Subsequently, catalytically hyperactivating mutations of EZH2 in somatic cells were identified in patients with non-Hodgkin lymphoma (NHL), indicating that PRC2 is critically involved in the progression of lymphoma [18,19,20]. The gene discussed is EZH2; the disease is non-Hodgkin lymphoma.